0001237899-19-000031.txt : 20191213
0001237899-19-000031.hdr.sgml : 20191213
20191213160539
ACCESSION NUMBER: 0001237899-19-000031
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191211
FILED AS OF DATE: 20191213
DATE AS OF CHANGE: 20191213
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SCHLEIFER LEONARD S
CENTRAL INDEX KEY: 0001218629
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19034
FILM NUMBER: 191284649
MAIL ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0000872589
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133444607
STATE OF INCORPORATION: NY
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
BUSINESS PHONE: 9148477000
MAIL ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
FORMER COMPANY:
FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19930328
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2019-12-11
0
0000872589
REGENERON PHARMACEUTICALS, INC.
REGN
0001218629
SCHLEIFER LEONARD S
777 OLD SAW MILL RIVER ROAD
TARRYTOWN
NY
10591
1
1
0
0
President & CEO
Common Stock
2019-12-12
4
M
0
124900
21.25
A
448962
D
Common Stock
2019-12-12
4
F
0
64754
377.16
D
384208
D
Common Stock
2019-12-12
4
M
0
187500
21.25
A
571708
D
Common Stock
2019-12-12
4
F
0
97209
377.16
D
474499
D
Common Stock
5816
I
By 401(k) Plan
Common Stock
100000
I
by 2019 GRAT
Non-Qualified Stock Option (right to buy)
21.25
2019-12-12
4
M
0
124900
0.0
D
2019-12-18
Common Stock
124900
187500
D
Non-Qualified Stock Option (right to buy)
21.25
2019-12-12
4
M
0
187500
0.0
D
2019-12-18
Common Stock
187500
0
D
Non-Qualified Stock Option (right to buy)
372.46
2019-12-11
4
A
0
81278
0.0
A
2029-12-11
Common Stock
81278
81278
D
Performance Stock Units
2019-12-11
4
A
0
25155
0.0
A
Common Stock
25155
25155
D
Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
The stock option award vests in four equal annual installments, commencing one year after the date of grant.
The option became exercisable with respect to all shares underlying the option on December 31, 2012, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2012.
Each performance-based restricted stock unit ("PSU") represents the contingent right to receive one share of the issuer's common stock at vesting. The amount reported reflects the maximum number of PSUs that may vest based upon the achievement of certain performance metrics related to total shareholder return over four-year and/or five-year performance periods ending on December 11, 2023 and December 11, 2024, respectively. Between 50% and 225% of the target number of PSUs (i.e., between 50% and 225% of 11,180 PSUs) may vest upon achievement of predetermined total shareholder return percentages derived from compound annual growth rates of 5% to 15% for the applicable performance period. If none of the performance metrics are achieved at the conclusion of the performance periods, the award expires.
/s/**Leonard S. Schleifer
2019-12-13